NASDAQ:CLRB

Cellectar Biosciences Stock Forecast, Price & News

$1.07

-0.02 (-1.83 %)

(As of 07/27/2021 11:30 AM ET)

Add

Compare

Today's Range

$1.06

▼

$1.08

50-Day Range

$1.02

▼

$1.82

52-Week Range

$1.01

▼

$2.98

Volume15,258 shs

Average Volume1.23 million shs

Market Capitalization$56.42 million

P/E RatioN/A

Dividend YieldN/A

Beta1.62

30 days | 90 days | 365 days | Advanced Chart

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

About Cellectar Biosciences

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest Down 26.1% in June
July 20, 2021 | americanbankingnews.com

Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
July 13, 2021 | finance.yahoo.com

Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)
July 12, 2021 | finance.yahoo.com

Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
July 8, 2021 | finance.yahoo.com

Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors
June 24, 2021 | finance.yahoo.com

Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 4, 2021 | finance.yahoo.com

Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 20, 2021 | finance.yahoo.com

Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
May 14, 2021 | finance.yahoo.com

Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
May 10, 2021 | finance.yahoo.com

Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico
April 27, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLRB
Previous Symbol
CUSIPN/A
CIK1279704
Webwww.cellectar.com
Phone608-441-8120
Employees11
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.76 per share
Price / Book1.41

Profitability

EPS (Most Recent Fiscal Year)($0.76)
Net Income$-15,090,000.00
Net MarginsN/A
Return on Equity-65.58%
Return on Assets-44.21%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares52,730,000
Market Cap$56.42 million
Next Earnings Date8/9/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.24 out of 5 stars

Medical Sector

968th out of 2,218 stocks

Pharmaceutical Preparations Industry

464th out of 869 stocks

3.5 Analyst's Opinion

Consensus Rating
Cellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.25, Cellectar Biosciences has a forecasted upside of 297.2% from its current price of $1.07.
Amount of Analyst Coverage
Cellectar Biosciences has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Cellectar Biosciences has received 229 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cellectar Biosciences has received 197 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cellectar Biosciences has received 53.76% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote “Outperform” if you believe CLRB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cellectar Biosciences does not currently pay a dividend.
Dividend Growth
Cellectar Biosciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.82% of the stock of Cellectar Biosciences is held by insiders.
Percentage Held by Institutions
Only 28.54% of the stock of Cellectar Biosciences is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Cellectar Biosciences are expected to decrease in the coming year, from ($0.46) to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cellectar Biosciences is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellectar Biosciences is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cellectar Biosciences has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

Is Cellectar Biosciences a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cellectar Biosciences stock.
View analyst ratings for Cellectar Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Cellectar Biosciences?

Wall Street analysts have given Cellectar Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellectar Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,590,000 shares, an increase of 40.7% from the June 30th total of 1,130,000 shares. Based on an average daily volume of 772,300 shares, the days-to-cover ratio is presently 2.1 days. Approximately 3.4% of the company's shares are sold short.
View Cellectar Biosciences' Short Interest.

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Cellectar Biosciences.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) posted its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.03.
View Cellectar Biosciences' earnings history.

How has Cellectar Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Cellectar Biosciences' stock was trading at $1.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLRB stock has decreased by 39.4% and is now trading at $1.09.
View which stocks have been most impacted by COVID-19.

When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work?

Shares of Cellectar Biosciences reverse split on the morning of Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CLRB?

3 analysts have issued 1 year target prices for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $5.50. On average, they expect Cellectar Biosciences' stock price to reach $4.25 in the next year. This suggests a possible upside of 289.9% from the stock's current price.
View analysts' price targets for Cellectar Biosciences or view top-rated stocks among Wall Street analysts.

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the following people:

Mr. James V. Caruso, Pres, CEO & Director (Age 62, Pay $807.5k)
Mr. Dov Elefant, VP & CFO (Age 54, Pay $450.99k)
Mr. Jarrod Longcor, Chief Bus. Officer (Age 48, Pay $491.01k)
Dr. John E. Friend II, M.D., Chief Medical Officer (Age 51)
Gregory J. Lynch Esq., Sec.

Who are some of Cellectar Biosciences' key competitors?

Some companies that are related to Cellectar Biosciences include Galera Therapeutics (GRTX), CTI BioPharma (CTIC), Harrow Health (HROW), TFF Pharmaceuticals (TFFP), Sierra Oncology (SRRA), Osmotica Pharmaceuticals (OSMT), Xeris Pharmaceuticals (XERS), BCTG Acquisition (BCTG), Reneo Pharmaceuticals (RPHM), Pieris Pharmaceuticals (PIRS), BELLUS Health (BLU), Checkpoint Therapeutics (CKPT), BioVie (BIVI), Tricida (TCDA) and Jaguar Health (JAGX).
View all of CLRB's competitors.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $1.09.

How much money does Cellectar Biosciences make?

Cellectar Biosciences has a market capitalization of $57.48 million. The biopharmaceutical company earns $-15,090,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does Cellectar Biosciences have?

Cellectar Biosciences employs 11 workers across the globe.

What is Cellectar Biosciences' official website?

The official website for Cellectar Biosciences is www.cellectar.com.

Where are Cellectar Biosciences' headquarters?

Cellectar Biosciences is headquartered at 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here